Australian Govt Needs To Tackle Low Biosimilar Awareness And Switching Concerns
This article was originally published in SRA
Executive Summary
The Australian government is facing something of an uphill struggle in convincing patients and healthcare professionals of the benefits of biosimilars, at least judging by a survey that has just been presented to the stakeholder reference group set up to advise on the government's biosimilar awareness strategy1.